Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
Tony Coles takes second neuroscience startup public as Yumanity reverse merges
5 years ago
Which big biopharma player should gamble $34B on a ripe rare-disease M&A target? An action-hungry top analyst fills in the blanks
5 years ago
Takeda gets a $2.2B deal for its OTC unit as debt-relief drive nears its end
5 years ago
Is Takeda’s post-Shire sell-off approaching its final days?
5 years ago
Covid-19 roundup: Fauci, Collins intervene to stop FDA plasma authorization, citing weak data; Roche, Regeneron try to take antibodies global
5 years ago
Coronavirus
J&J inks industry's latest bolt-on buyout with $6.5B deal to acquire Momenta, beefing up its autoimmune pipeline
5 years ago
Looking to expand beyond diabetes, Novo Nordisk enlists Evotec in CKD pact worth up to $179M per program
5 years ago
Daniel O’Day’s I/O dance continues, as Gilead and Tango expand deal up to $6B
5 years ago
Cell/Gene Tx
Blackstone finalizes R&D pact with Alnylam as part of earlier $2 billion investment
5 years ago
R&D
Taysha buys clinic-ready gene therapy from Abeona, bringing Steven Gray's portfolio back in one place
5 years ago
Cell/Gene Tx
Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology — with a potential IL-12 game-changer
5 years ago
How badly does Sanofi chief Paul Hudson want Principia? Enough to ink a $3.7B buyout deal, doubling down on MS
5 years ago
Eyeing in-vivo editing, Mammoth licenses Jennifer Doudna’s new CRISPR enzyme
5 years ago
R&D
Calliditas bets up to $102M on a biotech buyout, snagging a once-failed PBC drug
5 years ago
R&D
Qiagen investors spurn Thermo Fisher’s takeover offer, derailing a $12B+ deal
5 years ago
Galaxy Life Sciences lands $50 million deal to build in central Massachusetts biomanufacturing park
5 years ago
Novartis’ CAR-T partner in China wraps $383M take-private deal engineered by CEO
5 years ago
China
Cell/Gene Tx
Roche pulls a tumor micro-environment drug out of the freezer, hands it to a UK upstart
5 years ago
Perceptive births its first in-house startup — and it's a China play
5 years ago
Startups
China
Ligand scoops up Pfenex for up to $516M, adding proteins to their antibody chickens and delivery tech
5 years ago
R&D
Hunting a blockbuster, Bayer forges an $875M-plus M&A deal to acquire women’s health biotech
5 years ago
The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline
5 years ago
R&D
Biohaven adds nearly $1B in Nurtec deals with Royalty Pharma, Sixth Street
5 years ago
AbbVie abandons a pioneering CRISPR R&D alliance with Editas as Brent Saunders' deal is cast out
5 years ago
R&D
First page
Previous page
88
89
90
91
92
93
94
Next page
Last page